Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 01 2021
14 01 2021
Historique:
received:
28
08
2020
accepted:
09
12
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
11
8
2021
Statut:
epublish
Résumé
The purpose of this work was to investigate the distinct and common metabolic features of the malignant and benign thyroid lesions in reference to the non-transformed tissue from the contralateral gland (chronic thyroiditis and colloid goiter).
Identifiants
pubmed: 33446721
doi: 10.1038/s41598-020-79565-8
pii: 10.1038/s41598-020-79565-8
pmc: PMC7809111
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1344Références
Mazzaferri, E. L. Management of a solitary thyroid nodule. N. Engl. J. Med. 328, 553–559 (1993).
pubmed: 8426623
doi: 10.1056/NEJM199302253280807
Ezzat, S. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch. Internal Med. 154, 1838–1840 (1994).
doi: 10.1001/archinte.1994.00420160075010
Tan, G. Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann. Intern. Med. 126, 226 (1997).
pubmed: 9027275
doi: 10.7326/0003-4819-126-3-199702010-00009
La Vecchia, C. et al. Thyroid cancer mortality and incidence: A global overview. Int. J. Cancer 136, 2187–2195 (2014).
pubmed: 25284703
doi: 10.1002/ijc.29251
Fagin, J. & Wells, S. Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med. 375, 1054–1067 (2016).
pubmed: 27626519
pmcid: 5512163
doi: 10.1056/NEJMra1501993
Home. Who.int (2020). https://www.who.int/ .
Global Cancer Observatory. Gco.iarc.fr (2020). https://gco.iarc.fr/ .
Boufraqech, M. & Nilubol, N. Multi-omics signatures and translational potential to improve thyroid cancer patient outcome. Cancers 11, 1988 (2019).
pmcid: 6966476
doi: 10.3390/cancers11121988
Torregrossa, L. et al. Toward the reliable diagnosis of indeterminate thyroid lesions: A HRMAS NMR-based metabolomics case of study. J. Proteome Res. 11, 3317–3325 (2012).
pubmed: 22509853
doi: 10.1021/pr300105e
Deja, S. et al. Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions. PLoS One 8, 84637 (2013).
doi: 10.1371/journal.pone.0084637
Miccoli, P. et al. Metabolomics approach to thyroid nodules: A high-resolution magic-angle spinning nuclear magnetic resonance-based study. Surgery 152, 1118–1124 (2012).
pubmed: 23158182
doi: 10.1016/j.surg.2012.08.037
Ryoo, I. et al. Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: Potential application for the preoperative diagnosis of thyroid cancer. Sci. Rep. 6, 20 (2016).
doi: 10.1038/srep30075
Rezig, L. et al. Diagnosis of post-surgical fine-needle aspiration biopsies of thyroid lesions with indeterminate cytology using HRMAS NMR-based metabolomics. Metabolomics 14, 20 (2018).
doi: 10.1007/s11306-018-1437-6
Tian, Y. et al. Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Sci. Rep. 5, 20 (2015).
doi: 10.1038/srep14869
Li, Y. et al. Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study. Int. J. Mol. Med. 41, 3006–3014 (2018).
pubmed: 29484373
Xu, Y. et al. Distinct metabolomic profiles of papillary thyroid carcinoma and benign thyroid adenoma. J. Proteome Res. 14, 3315–3321 (2015).
pubmed: 26130307
doi: 10.1021/acs.jproteome.5b00351
Aran, D. et al. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat. Commun. 8, 20 (2017).
doi: 10.1038/s41467-017-01027-z
Yim, J. et al. Identification of tissue-specific DNA methylation signatures for thyroid nodule diagnostics. Clin. Cancer Res. 25, 544–551 (2018).
pubmed: 30093451
pmcid: 6335179
doi: 10.1158/1078-0432.CCR-18-0841
Paparodis, R. et al. Incidentally discovered papillary thyroid microcarcinomas are more frequently found in patients with chronic lymphocytic thyroiditis than with multinodular Goiter or Graves’ disease. Thyroid 30, 531–535 (2020).
pubmed: 31950881
doi: 10.1089/thy.2019.0347
Boi, F., Pani, F. & Mariotti, S. Thyroid autoimmunity and thyroid cancer: Review focused on cytological studies. Eur. Thyroid J. 6, 178–186 (2017).
pubmed: 28868258
pmcid: 5567004
doi: 10.1159/000468928
Kebebew, E., Treseler, P., Ituarte, P. & Clark, O. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J. Surg. 25, 632–637 (2001).
pubmed: 11369991
doi: 10.1007/s002680020165
Wheelock, Å. & Wheelock, C. Trials and tribulations of ‘omics data analysis: Assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol. BioSyst. 9, 2589 (2013).
pubmed: 23999822
doi: 10.1039/c3mb70194h
Wiklund, S. et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically Interesting compounds using OPLS class models. Anal. Chem. 80, 115–122 (2008).
pubmed: 18027910
doi: 10.1021/ac0713510
Chong, J. et al. MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 46, W486–W494 (2018).
pubmed: 29762782
pmcid: 6030889
doi: 10.1093/nar/gky310
Xia, J. & Wishart, D. MetPA: A web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 26, 2342–2344 (2010).
pubmed: 20628077
doi: 10.1093/bioinformatics/btq418
Cambiaghi, A., Ferrario, M. & Masseroli, M. Analysis of metabolomic data: Tools, current strategies and future challenges for omics data integration. Brief. Bioinform. https://doi.org/10.1093/bib/bbw031 (2016).
doi: 10.1093/bib/bbw031
Gibellini, F. & Smith, T. The Kennedy pathway-De novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life https://doi.org/10.1002/iub.337 (2010).
doi: 10.1002/iub.337
pubmed: 20503434
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
pubmed: 13298683
doi: 10.1126/science.123.3191.309
Kachel, P. et al. Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue. BMC Cancer 15, 20 (2015).
doi: 10.1186/s12885-015-1135-y
Haber, R., Weiser, K., Pritsker, A., Reder, I. & Burstein, D. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 7, 363–367 (1997).
pubmed: 9226204
doi: 10.1089/thy.1997.7.363
Matsuzu, K. et al. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 14, 806–812 (2004).
pubmed: 15588375
doi: 10.1089/thy.2004.14.806
Jóźwiak, P., Krześlak, A., Pomorski, L. & Lipińska, A. Expression of hypoxia-related glucose transporters GLUT1 and GLUT3 in benign, malignant and non-neoplastic thyroid lesions. Mol. Med. Rep. 6, 601–606 (2012).
pubmed: 22752218
doi: 10.3892/mmr.2012.969
Gill, S. K. & Tassone, P. Thyroid cancer metabolism: A review. J. Thyroid Disord. Ther. 5, 20 (2016).
doi: 10.4172/2167-7948.C1.003
Singh, S., Tan, M. & Rameshwar, P. Cancer metabolism: Targeting metabolic pathways in cancer therapy. Cancer Lett. 356, 147–148 (2015).
pubmed: 24956174
doi: 10.1016/j.canlet.2014.06.002
Amelio, I., Cutruzzolá, F., Antonov, A., Agostini, M. & Melino, G. Serine and glycine metabolism in cancer. Trends Biochem. Sci. 39, 191–198 (2014).
pubmed: 24657017
pmcid: 3989988
doi: 10.1016/j.tibs.2014.02.004
Ciavardelli, D., Bellomo, M., Consalvo, A., Crescimanno, C. & Vella, V. Metabolic alterations of thyroid cancer as potential therapeutic targets. Biomed. Res. Int. 2017, 1–10 (2017).
doi: 10.1155/2017/2545031
Hitosugi, T. & Chen, J. Post-translational modifications and the Warburg effect. Oncogene 33, 4279–4285 (2013).
pubmed: 24096483
doi: 10.1038/onc.2013.406
Sun, W., Kim, H., Jung, W. & Koo, J. Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype. J. Transl. Med. 14, 20 (2016).
doi: 10.1186/s12967-016-0915-8
Wen, S. et al. Metabolic reprogramming and its clinical application in thyroid cancer (Review). Oncol. Lett. https://doi.org/10.3892/ol.2019.10485 (2019).
doi: 10.3892/ol.2019.10485
pubmed: 31897151
pmcid: 6924115
Zhou, Q. et al. Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents. Pediatr. Surg. Int. 36, 145–153 (2019).
pubmed: 31576470
doi: 10.1007/s00383-019-04584-0
Lean, C. Diagnosis of follicular thyroid lesions by proton magnetic resonance on fine needle biopsy. J. Clin. Endocrinol. Metab. 80, 1306–1311 (1995).
pubmed: 7714105
Russell, P. et al. Proton magnetic resonance and human thyroid neoplasia I: Discrimination between benign and malignant neoplasms. Am. J. Med. 96, 383–388 (1994).
pubmed: 8166160
doi: 10.1016/0002-9343(94)90071-X
Abdel-Haleem, A. et al. The emerging facets of non-cancerous Warburg effect. Front. Endocrinol. 8, 20 (2017).
doi: 10.3389/fendo.2017.00279
Abooshahab, R., Gholami, M., Sanoie, M., Azizi, F. & Hedayati, M. Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation. Endocrine 65, 1–14 (2019).
pubmed: 30937722
doi: 10.1007/s12020-019-01904-1
Khatami, F. et al. Oncometabolites as biomarkers in thyroid cancer: A systematic review. Cancer Manag. Res. 11, 1829–1841 (2019).
pubmed: 30881111
pmcid: 6395057
doi: 10.2147/CMAR.S188661
Yu, Y. et al. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer. J. Mol. Med. 96, 777–790 (2018).
pubmed: 29942976
doi: 10.1007/s00109-018-1659-0
Shah, A., Wang, Z. & Ma, J. Glutamine metabolism and its role in immunity, a comprehensive review. Animals 10, 326 (2020).
doi: 10.3390/ani10020326
pmcid: 7070879
Tugnoli, V. et al. Ex vivo HR-MAS magnetic resonance spectroscopy of human gastric adenocarcinomas: A comparison with healthy gastric mucosa. Oncol. Rep. https://doi.org/10.3892/or.16.3.543 (2006).
doi: 10.3892/or.16.3.543
pubmed: 16865254
Tugnoli, V. Identification of mobile lipids in human cancer tissues by ex vivo diffusion edited HR-MAS MRS. Oncol. Rep. 22, 20 (2009).
doi: 10.3892/or_00000592
Ma, Y. et al. Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Lett. 435, 92–100 (2018).
pubmed: 30102953
pmcid: 6240910
doi: 10.1016/j.canlet.2018.08.006
Lu, J. et al. Non-invasive diagnosis of papillary thyroid microcarcinoma: A NMR-based metabolomics approach. Oncotarget 7, 81768–81777 (2016).
pubmed: 27835583
pmcid: 5348428
doi: 10.18632/oncotarget.13178
Wang, R. et al. Cpt1c regulated by AMPK promotes papillary thyroid carcinomas cells survival under metabolic stress conditions. J. Cancer 8, 3675–3681 (2017).
pubmed: 29151954
pmcid: 5688920
doi: 10.7150/jca.21148
Fallahi, P. et al. Myo-inositol in autoimmune thyroiditis, and hypothyroidism. Rev. Endocrine Metab. Disord. 19, 349–354 (2018).
doi: 10.1007/s11154-018-9477-9
Jóźwiak, P. et al. Expression of hypoxia inducible factor 1α and 2α and its association with vitamin C level in thyroid lesions. J. Biomed. Sci. 24, 20 (2017).
doi: 10.1186/s12929-017-0388-y
Renault, M., Shintu, L., Piotto, M. & Caldarelli, S. Slow-spinning low-sideband HR-MAS NMR spectroscopy: Delicate analysis of biological samples. Sci. Rep. 3, 20 (2013).
doi: 10.1038/srep03349